ARTICLE | Clinical News
Phase III vardenafil results
June 25, 2001 7:00 AM UTC
Bayer (FSE:BAYG) reported that in a placebo-controlled Phase III study of its vardenafil phosphodiesterase-5 (PDE-5) inhibitor in 452 men with type 1 or 2 diabetes, 72% of men treated with 20 mg varde...